Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
Avapritinib, an approved orally available medication, reduced tumor size in a subset of children and young adults with treatment-resistant high-grade gliomas, a study shows.
Treatment with AbbVie’s Elahere (mirvetuximab soravtansine) reduced the risk of death by 32% in women with difficult-to-treat epithelial ovarian cancer over standard chemotherapy. That’s according…
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…